What is TECLens?
Based in Stamford, Connecticut, TECLens is pioneering a non-invasive cornea cross-linking procedure designed to treat keratoconus, low order myopia, and eventually presbyopia. The company's core technology, the CXLens, is a single-use disposable contact lens paired with a sophisticated control system. This system enables simultaneous treatment of both eyes, utilizing integrated real-time ultrasound feedback and patterned ultraviolet light delivery. By offering a safe, simple, and permanent alternative to conventional corrective measures like eyeglasses, contact lenses, and LASIK, TECLens is addressing a massive, underserved global patient population suffering from refractive errors.
How much funding has TECLens raised?
TECLens has raised a total of $15.7M across 3 funding rounds:
Private Equity
$1.2M
Series A
$9.3M
Debt
$5.2M
Private Equity (2017): $1.2M, investors not publicly disclosed
Series A (2025): $9.3M led by Yonjin Venture, Sunmed Capital, Rimonci Capital, and Johnson & Johnson Innovation
Debt (2026): $5.2M, investors not publicly disclosed
Key Investors in TECLens
Yonjin Venture
A venture firm focused on identifying and supporting innovative technologies across the therapeutics, diagnostics, and medical device sectors.
Sunmed Capital
A private equity and venture capital firm specializing in the healthcare and medical technology industries.
Rimonci Capital
A cross-border investment firm dedicated to the China-Israel corridor, with a specific mandate for high-potential medical device and cybersecurity ventures.
What's next for TECLens?
With this latest round of financing, TECLens is well-positioned to scale its clinical operations and refine its regulatory strategy. The company's roadmap focuses on advancing its proprietary CXLens technology through rigorous clinical trials to secure necessary approvals for commercialization. As the firm moves deeper into its lifecycle, the focus will shift toward establishing manufacturing scalability and building the necessary infrastructure to support a global rollout. The strategic backing from specialized medical device investors provides not only the necessary liquidity but also the industry expertise required to navigate the complex regulatory landscape of ophthalmic healthcare. Future milestones will likely center on expanding the indications for its cross-linking platform, potentially setting a new standard of care in refractive medicine.
See full TECLens company page
